• Thurs news: Amgen reaps Horizon buyout rewards in Q3. Baxter exits China IV market. Big Pharma earnings. Novo takes steps to end shortages. Roche Alzheimer’s test. See more on our front page


What will become of the K2M and Stryker Spine Salesforce?

anonymous

Guest
Does anyone have any thoughts or insight regarding what will become of the K2M salesforce following the acquisition of K2M by Stryker aside from the obvious thoughts of Stryker kicking K2M reps out and staking a claim? The move making K2M's CEO Eric Major is interesting and may bode well for K2M ground forces...no? There are many ways to analyze this, but I wanted to start a thread to get the discussion going.
 




Been around a while, used to work for Stryker. Usually, they absorb the business and mandate that key personnel stay on board for 12-18 months to ensure smooth transition, but mainly so no customers get pissed off. Sales force is evaluated for its current business revenue, and decisions are made to keep or fire field sales reps. All depends on how well the K2M territories are doing and the sustained growth shown in historical data. The VP's and marketing folks from K2M will pitch and teach the product lines to Stryker until they're no longer needed and will be evaluated on their presentations throughout the acquisition. If they suck, they'll be given a door to exit stage left. Survival of the fittest, welcome to life at Stryker. My advice is to stay up late and get your "bro" time in with all the Stryker folks, pound your beers, and fist bump until you can't take it anymore and hope you hang on. Oh, better go buy yourself some hair gel if you're not a current user.
 




Stryker bought K2M, but K2M took Stryker over. They kept virtually all the K2M leadership team, marketing, engineering, field management, distributors, sales reps. It was Stryker people faced the axe when a choice had to be made. But here's the funny thing: K2M succeeded because it was K2M. If will fail now that it's Stryker. Oil and water don't mix.